SummaryBRAFV600E drives tumors by dysregulating ERK signaling. In these tumors, we show that high levels of ERK-dependent negative feedback potently suppress ligand-dependent mitogenic signaling and Ras function. BRAFV600E activation is Ras independent and it signals as a RAF-inhibitor-sensitive monomer. RAF inhibitors potently inhibit RAF monomers and ERK signaling, causing relief of ERK-dependent feedback, reactivation of ligand-dependent signal transduction, increased Ras-GTP, and generation of RAF-inhibitor-resistant RAF dimers. This results in a rebound in ERK activity and culminates in a new steady state, wherein ERK signaling is elevated compared to its initial nadir after RAF inhibition. In this state, ERK signaling is RAF inhibitor...
RAF inhibitors unexpectedly induce ERK signaling in normal and tumor cells with elevated RAS activit...
SummaryERK signaling requires RAS-induced RAF dimerization and is limited by feedback. Activated BRA...
MEK inhibitors are clinically active in BRAFV600E melanomas but only marginally so in KRAS mutant tu...
BRAFV600E drives tumors by dysregulating ERK signaling. Here we show that, in these tumors, high le...
Tumors with mutant BRAF are dependent on the RAF/MEK/ERK signaling pathway for their growth1-3. We f...
RAF inhibitors have the unique property of transactivating RAS-dependent RAF dimers in most cells bu...
Tumours with mutant BRAF are dependent on the RAF-MEK-ERK signalling pathway for their growth. We fo...
In BRAF V600E melanoma patients, RAF inhibitor treatment causes a MEK-inhibitor-sensitive, RAF-inhib...
Summary Activated RAS promotes dimerization of members of the RAF kinase family1-3. ATP-competitive ...
The identification of BRAF V600E as a driving mutation in approximately 50% of melanoma and the subs...
Clinically used RAF inhibitors are ineffective in RAS-mutant tumors because they enhance homo- and h...
The Ras-Raf-MEK-ERK signaling pathway, the first well-established MAPK pathway, plays essential role...
The classical ERK/MAPK signalling pathway regulated proliferation, differentiation and survival. At ...
SummaryMEK inhibitors are clinically active in BRAFV600E melanomas but only marginally so in KRAS mu...
Summary: ATP-competitive RAF inhibitors elicit profound but often temporary antitumor responses in ...
RAF inhibitors unexpectedly induce ERK signaling in normal and tumor cells with elevated RAS activit...
SummaryERK signaling requires RAS-induced RAF dimerization and is limited by feedback. Activated BRA...
MEK inhibitors are clinically active in BRAFV600E melanomas but only marginally so in KRAS mutant tu...
BRAFV600E drives tumors by dysregulating ERK signaling. Here we show that, in these tumors, high le...
Tumors with mutant BRAF are dependent on the RAF/MEK/ERK signaling pathway for their growth1-3. We f...
RAF inhibitors have the unique property of transactivating RAS-dependent RAF dimers in most cells bu...
Tumours with mutant BRAF are dependent on the RAF-MEK-ERK signalling pathway for their growth. We fo...
In BRAF V600E melanoma patients, RAF inhibitor treatment causes a MEK-inhibitor-sensitive, RAF-inhib...
Summary Activated RAS promotes dimerization of members of the RAF kinase family1-3. ATP-competitive ...
The identification of BRAF V600E as a driving mutation in approximately 50% of melanoma and the subs...
Clinically used RAF inhibitors are ineffective in RAS-mutant tumors because they enhance homo- and h...
The Ras-Raf-MEK-ERK signaling pathway, the first well-established MAPK pathway, plays essential role...
The classical ERK/MAPK signalling pathway regulated proliferation, differentiation and survival. At ...
SummaryMEK inhibitors are clinically active in BRAFV600E melanomas but only marginally so in KRAS mu...
Summary: ATP-competitive RAF inhibitors elicit profound but often temporary antitumor responses in ...
RAF inhibitors unexpectedly induce ERK signaling in normal and tumor cells with elevated RAS activit...
SummaryERK signaling requires RAS-induced RAF dimerization and is limited by feedback. Activated BRA...
MEK inhibitors are clinically active in BRAFV600E melanomas but only marginally so in KRAS mutant tu...